L-dopa for parkinsonism.
D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000145:classification / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000139:chemically induced; D013997:Time Factors
D004295:Dihydroxyphenylalanine; D000547:Amantadine